Article
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Cancer discovery - 1 Jul 2018
Subbiah Vivek, Gainor Justin F, Rahal Rami, Brubaker Jason D, Kim Joseph L, Maynard Michelle, Hu Wei, Cao Qiongfang, Sheets Michael P, Wilson Douglas, Wilson Kevin J, DiPietro Lucian, Fleming Paul, Palmer Michael, Hu Mimi I, Wirth Lori, Brose Marcia S, Ou Sai-Hong Ignatius, Taylor Matthew, Garralda Elena, Miller Stephen, Wolf Beni, Lengauer Christoph, Guzi Timothy, Evans Erica K
Abstract excerpt
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapies have been designed to target RET; treatment has been limited to multikinase inhibitors (MKI), which can have significant off-target toxicities and limited efficacy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.